Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Aging Knowl. Environ., 9 February 2005
Vol. 2005, Issue 6, p. pe4
[DOI: 10.1126/sageke.2005.6.pe4]

PERSPECTIVES

Drug Discovery in Neurodegenerative Diseases

Hugo Geerts, John Q. Trojanowski, and Virginia M.-Y. Lee

The authors are at In Silico Biosciences (H.G.) and the Center for Neurodegenerative Disease Research, the Institute on Aging, and the Department of Pathology and Laboratory Medicine (H.G., J.Q.T., and V.M.Y.L.), University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. E-mail: Hugo-Geerts{at}In-Silico-Biosciences.com (H.G.)

http://sageke.sciencemag.org/cgi/content/full/2005/6/pe4

Key Words: Alzheimer's disease • drug discovery • neurodegeneration • prion • protein misfolding • tauopathies

Abstract: This meeting report documents the exciting ongoing research aimed at developing new therapeutic agents for neurodegenerative diseases at the interface between academia and industry, and illustrates the direction the NIH "roadmap" for medical research is taking. Some of the projects have resulted in very promising drugs, identified and developed by academic centers, entering clinical trials.

Citation: H. Geerts, J. Q. Trojanowski, V. M.-Y. Lee, Drug Discovery in Neurodegenerative Diseases. Sci. Aging Knowl. Environ. 2005 (6), pe4 (2005).

Read the Full Text







To Advertise     Find Products


Science of Aging Knowledge Environment. ISSN 1539-6150